• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

NantKwest launches clinical trial for natural killer cells

January 24, 2017 By Sarah Faulkner

NantKwest launches clinical trial for natural killer cellsNantKwest Inc. (NSDQ:NK) said yesterday that the FDA approved an Investigational New Drug Application for its natural killer cell therapy phase I clinical study. The company is evaluating its genetically engineered, allogenic natural killer cell therapy in patients with cancer.

The study, which NantKwest touts as the 1st of its kind, will determine the safety of natural killer cell monotherapy given intravenously once a week in as many as 16 patients with metastatic or locally advanced solid tumors.

Other goals of the study include determining an objective response rate, progression-free survival, overall survival and any correlation between tumor molecular profiles and patient outcomes, according to NantKwest.

“We are thrilled to have received notification from the FDA that our 1st haNK cell therapy program has been authorized to proceed into Phase I clinical trials and are focused on moving swiftly to begin this study,” chairman & CEO Dr. Patrick Soon-Shiong said in prepared remarks. “The FDA’s authorization to initiate this clinical trial achieves a significant milestone for NantKwest as we begin clinical investigation of the use of haNK cell therapy for the treatment of cancer in a wide range of cancer types.”

The Culver City, Calif.-based company’s cell therapy is designed to optimize the role that natural killer cells play in mediating immunity, enhancing immune responses and improving anti-tumor responses.

In preclinical studies, the addition of high affinity natural killer cells to various therapeutic antibodies increased tumor cell killing compared to the antibody alone. The company said that its 1st clinical study is designed to provide the required safety data needed to transition to haNK-antibody combination studies.

NK shares were trading at $5.88 per share in morning activity, down -7.9%.

Filed Under: Clinical Trials, Featured, Food & Drug Administration (FDA), Immunotherapy, Oncology Tagged With: NantKwest

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS